Sito in Italia dove è possibile acquistare la consegna acquisto Viagra a buon mercato e di alta qualità in ogni parte del mondo.

I. wissenschaftliche publikationen

Publikationen mit Peer Review
Lüthy R, Münch R, Blaser J, Bhend HJ, Siegenthaler W. Human pharmacology of cefotaxime (HR 756), a new cephalosporin. Antimicrob Agents Chemother 16: 127-133, 1979 Lüthy R, Blaser J, Bonetti A, Simmen H, Wise R, Siegenthaler W. Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother 20:567-575, 1981 Münch R, Lüthy R, Blaser J, Siegenthaler W. Human Pharmacokinetics and CSF Penetration of Clavulanic Acid. J Antimicrob Chemother 8: 29-37, 1981 Blaser J, Rieder H, Niederer P, Lüthy R. Biological variability of multiple dose pharmacokinetics of netilmicin in man. Eur J Clin Pharm 24: 399-406, 1983 Putzi R, Blaser J, Lüthy R, Wehrli R, Siegenthaler W. Side-effects due to intravenous infusion of erythromycin. Infection 11: 161-164, 1983 Blaser J, Rüttimann S, Bhend HJ, Lüthy R. Increase of amikacin half-life during therapy in patients with renal insufficiency. Antimicrob Agents Chemother 23: 888-891, 1983 Blaser J, Bauernfeind A, Vogt M, Lüthy R. Monotherapie von systemischen Pseudomonas aeruginosa Infektionen mit Ceftazidim: Ursachen therapeutischer Misserfolge. Deut Med Wschr 108: 1312-1317, 1983 Zinner SH, Blaser J, Stone BB, Groner MC. Use of an in vitro kinetic model to study antibiotic combinations. J Antimicrob Chemother 15, Suppl A: 221-226, 1985 Blaser J. In vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J Antimicrob Chemother 15, Suppl A: 125-130, 1985 10. Blaser J, Stone BB, Zinner SH. Efficacy of intermittent versus continuous administration of netilmicin in a new two compartment in vitro model. Antimicrob Agents Chemother 27:343-349, 1985 11. Blaser J, Stone BB, Groner MC, Zinner SH. Impact of netilmicin regimens on the activity of ceftazidime-netilmicin combinations against Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 28: 64-68, 1985 12. Blaser J, Stone BB, Zinner SH. Two compartment kinetic model with multiple artificial capillary units. J Antimicrob Chemother 15,A: 131-137, 1985 13. Ledergerber B, Blaser J, Lüthy R. Computer-controlled in vitro simulation of multiple dosing regimens. J Antimicrob Chemother,A: 169-173, 1985 14. Blaser J, Simmen HP, Gonzenbach HR, Sonnabend W, Lüthy R. Aminoglycoside monitoring: Timing of 'peak' levels is critical. Therapeutic Drug Monitoring, 7: 303-307, 1985 15. Blaser J, Dudley MN, Gilbert D, Zinner SH. Influence of media and method on the in vitro susceptibility of Pseudomonas aeruginosa and other bacteria to ciprofloxacin and enoxacin. Antimicrob Agents Chemother 29:927-929, 1986 In vitro studies of antibiotic combinations with a special emphasis on the evaluation of newly developed methods. J Antimicrob Chemotherapy 17, Suppl A: 1-5, 1986 17. Blaser J, Münch R, Lüthy R. Human pharmacology of 5-epi-sisomicin (Sch 22591) following intramuscular administration. J Antimicrob Chemother, 19:233-238, 1987 18. Blaser J, Lüthy R, Rietiker S, Ledergerber B, Täuber MG. Prevalence of HIV antibodies in groups at risk in Zürich. Klin Wochenschr 65:245-246, 1987 (1992 Namenswechsel zu J molecular medicine, impact factor z.Zt. 19. Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 31:1054-1060, 1987 Comparative study on antagonistic effects of low pH and cation supplementation on in vitro activity of quinolones and aminoglycosides against Pseudomonas aeruginosa. J Antimicrob Chemother, 22:15-22, 1988 Long term accuracy of fluorescence polarization immunoassays for gentamicin, tobramycin, netilmicin and vancomycin. J Antimicrob Chemother 24:797-803, 1989 22. Dudley MN, Blaser J, Gilbert D, Zinner SH. Significance of "extravascular" protein binding for antimicrobial pharmacodynamics in an in vitro capillary model of infection. Antimicrob Agents Chemother 34:98-101, 1990 23. Bellido F, Veuthey C, Blaser J, Bauernfeind A, Pechère JC. Novel resistance to imipenem associated with an altered PBP-4 in a Pseudomonas aeruginosa clinical isolate. J Antimicrob Chemother 25:57-68, 1990 24. Schlaeffer F, Blaser J, Laxon J, Zinner S. Enhancement of leucocyte killing of resistant bacteria selected during exposure to aminoglycosides or quinolones. J Antimicrob Chemother 25:941-948, 1990 Interactions of antimicrobial combinations in vitro: the relativity of synergism. Scand J Infect Dis, S74:71-79, 1991 26. Dudley MN, Blaser J, Gilbert D, Mayer KH, Zinner SH. Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous vs. staggered administration in an in vitro model of infection. J Infect Dis 164: 499 - 506, 1991 Efficacy of Once- and Thrice-Daily Dosing of Aminoglycosides in In Vitro Models of Infection. J Antimicrob Chemother 27, C:21-28, 1991 28. Blaser J, Rieder HL, Lüthy R. Interface Area to Volume Ratio of Interstitial Fluid in Humans Determined by Pharmacokinetic Analysis of Netilmicin in Small and Large Skin Blisters. Antimicrob Agents Chemother 35:837-839, 1991 29. Opravil M, Fierz W, Matter L, Blaser J, Lüthy R. Poor antibody response after tetanus and pneumococcal vaccination in immuno-compromised, HIV-infected patients. Clin exp Immunol 84:185-189, 1991 Amikacin, ceftazidime and flucloxacillin against suspended and adherent Pseudomonas aeruginosa and Staphylococcus epidermidis in an in vitro model of infection. J Infect Dis 165: 281- 289, 1992 Analysis of pH and pO2 in absesses, peritoneal and drainage fluid in the presence and absence of bacterial infection during and following abdominal surgery. Amer J Surg, 165: 24-27, 1993 32. Simmen HP, Battaglia H, Kossmann T, Blaser J. Effect of pH in peritoneal fluid on outcome of aminoglycoside treatment in intra-abdominal infections. World J Surg, 17: 393-397, 1993 33. Blaser J, Joos B, Opravil M, Lüthy R. Varaibility of Serum Concentrations of Trimethoprim and Sulfamethoxazole During High Dose Therapy. Infection 21:206-209, 1993 34. König C, Simmen HP, Blaser J. Effect of Pathological Changes of pH, pO2, and pCO2 on the Activity of Antimicrobial Activity in Vitro. Europ J Clin Microb Infect Dis 12: 519-526, 1993 35. Blaser J, König C, Simmen HP, Thurnheer U. Monitoring serum concentrations for once-daily dosing regimens of netilmicin. J Antimicrob Chemother 33: 341-348, 1994 36. Simmen HP, Battaglia H, Giovanoli P, Blaser J. Analysis of pH, pO2 and pCO2 in drainage fluid allows for rapid detection of infectious complications during the follow-up period after abdominal surgery. Infection 22: 386-389, 1994 37. Flückiger U, Moreillon P, Blaser J, Bickle M, Glauser MP, Francioli P. Simulation of amoxicillin pharmacokinetics in humans for the prevention of Streptococcal endocarditis in rats. Antimicrob Agents Chemother 38: 2846-2849, 1994 38. Fluckiger U, Francioli P, Blaser J, Glauser MP, Moreillon P. Role of amoxicillin serum levels for successful prophylaxis of experimental endocarditis due to tolerant streptococci. J Infect Dis 169: 1397-1400, 1994 39. Simmen HP, Battaglia H, Giovanoli P, Hänseler E, Blaser J. Biochemical analyses of peritoneal fluid in patients with and without bacterial infection. Eur J Surg 161:23-27, 1995 40. Blaser J, König C, Fatio R, Follath F, Cometta A, Glauser M, and members of the IATCG-EORTC. Multicenter Quality Control Study of Amikacin Assay for Monitoring Once-Daily Dosing Regimens. Therapeutic Drug Monitoring 17: 133-136, 1995 41. Kunz S, Junker U, Blaser J, Joos B, Meyer B, Zak O, O'Reilly T. The scid Mouse as an Experimental Model for the Evaluation of Anti-Pneumocystis carinii Therapy. J Antimicrob Chemother 36: 137-155, 1995 42. Blaser J, Vergères P, Widmer AF, Zimmerli W. In-vivo Verification of an In-vitro Model of Antibiotic Treatment of Device-related Infection. Antimicrob Agents Chemother 39: 1134-1139, 1995 Effect of pO2 and pH on Synergy of Tazobactam and Beta-Lactam Antibiotics against Beta-Lactamase Producing Enterobacteriaceae. J Antimicrob Chemother 36: 513-519, 1995 44. Blaser J, Simmen HP, Thurnheer U, König C, Lüthy R. Nephrotoxicity, High Frequency Ototoxicity, Efficacy and Serum Kinetics of Once versus Thrice Daily Dosing of Netilmicin in Patients with Serious Infections. J Antimicrob Chemother 36: 803-814, 1995 45. Joos B, Blaser J, Opravil M, Chave JP, Lüthy R. Monitoring of co-trimoxazole concentrations in serum during treatment of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 39: 2661-2666, 1995 Once- versus thrice-daily netilmicin combined with amoxicillin, penicillin, or vancomycin against Enterococcus faecalis in a pharmacodynamic in vitro model. Antimicrob Agents Chemother 40: 2258-2261, 1996 47. König C, Ruffieux K, Wintermantel E, Blaser J. Autosterilization of Biodegradable Implants by the Injection Moulding Process. J Biomed Mater Res (Applied Biomat) 38: 115-119, 1997 48. Schwank S, Rajacic Z, Zimmerli W, Blaser J. Impact of bacterial biofilm formation on in vitro and in vivo activites of antibiotics. Antimicrob Agents Chemother 42: 895-898, 1998 49. König C, Simmen HP, Blaser J. Bacterial concentrations in pus ans infected peritoneal fluid - Implications for bactericidal activity of antibiotics. J Antimicrob Chemother,42:227-232, 1998 50. Matthews F, Blaser J, Russi EW, Bloch KE. Peripheral database module for clinical management and research in sleep medicine. Technol Health Care, 7:331-342, 1999 51. König C, Schwank S, Blaser J. Factors compromising antibiotic activity against biofilms of Staphylococcus epidermidis. Eur J Clin Microbiol Infect Dis 20:20-26, 2001 Spracherkennung im klinischen Alltag, ein Pilotversuch am Universitätsspital Zürich. Praxis 91: 831–835, 2002 53. Kucher N, Puck M, Blaser J, Bucklar G, Eschmann E, Lüscher TF. Physician compliance with advanced electronic alerts for preventing venous thromboembolism among hospitalized medical patients J Thrombosis Haemostasis 7: 1291–1296, 2009 Übersichtsarbeiten und übrige Publikationen
54. Blaser J, Friedli P, Niederer P, Anliker M. Pharmakokinetische Modellierung mit Hilfe eines Mikrocomputers. Medita 7:12-15, 1977 55. Münch R., Lüthy R, Blaser J, Siegenthaler W. Clavulanic acid: Human pharmacokinetics and CSF penetration. In: Current Chemotherapy and Infectious Diseases, American Society for Microbiology, Washington, D.C., Vol. 1:345-347, 1980 Variabilität in der Pharmakokinetik von Aminoglykosid Antibiotika. Dissertation ETH Nr. 6927, 1981 57. Lüthy R, Blaser J, Bonetti A, Simmen H, Wise R, Siegenthaler W. Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam and ceftazidime. Rev Infect Dis 4, Suppl: 581-584, 1982 58. Blaser J, Rüttimann S, Bhend HJ, Lüthy R. Increase of amikacin half-life during therapy. Chemotherapia 2, Suppl 5: 177-178, 1983 Efficacy of DNA-gyrase inhibitors in experimental animal studies and in pharmacokinetic in vitro models. Research and Clinical Forums 7: 45-54, 1985 60. Blaser J, Stone BB, Gilbert DH, Zinner SH. The effect of single and multiple doses of azlocillin and netilmicin in a pharmacokinetic model compared to standard in vitro methods. In: Recent Advances in Chemotherapy (Ed. J Ishigami), University of Tokyo Press, 690-691, 1985 Pharmakokinetisches in vitro Modell zur Untersuchung der Wirkung und der optimalen Dosierung von Antibiotika. ALTEX 5:16-20, 12.1986 Laboratory support for choosing and monitoring antimicrobial therapy in severly ill patients. Amer J Med 80, Suppl 5C:59-63, 1986 In vitro models in the study of antibiotic therapy of infections in neutropenic patients. Amer J Med 80, Suppl 5C:40-44, 1986 64. Zinner SH, Dudley M, Blaser J. In vitro models for the study of combination antibiotic therapy in neutropenic patients. Amer J Med 80, Suppl 6B:156-160, 1986 In vitro models for the study of antibiotic activities. In: Progress in Drug Research, Vol. 31 (Ed.: E. Jucker, U. Meyer) Birkhäuser Verlag, 349-381, 1987 Methodology and evaluation of pharmacokinetic in vitro models of antimicrobial chemotherapy. Chemiatherapia 6 (Suppl. 2): 239, 1987 67. Dudley MN, Blaser J, Gilbert D, Zinner SH. Bactericidal activity of ciprofloxacin against Pseudomonas aeruginosa and other bacteria in an in vitro two-compartment capillary model. Rev Infect Dis 10 (Suppl.1): 34-35, 1988 68. Schlaeffer F, Laxon J, Blaser J, Zinner SH. Ciprofloxacin enhanced leukocyte killing of drug induced resistant bacteria. Rev Infect Dis 10 (Suppl. 1): 32-33, 1988 69. Blaser J, Gilbert D, Zinner SH. Effect of enoxacin with and without leukocytes against Staphylococcus aureus in a pharmacokinetic model. Rev Infect Dis 10 (Suppl. 1): 33-34, 1988 Alternativen zu Tierversuchen bei der Untersuchung der Pharmakodynamik von antibakteriellen Chemotherapeutika. Habilitationsschrift an der Universität Zürich, 1989 Wie viele Zürcher sind vom AIDS-Virus infiziert? Ein epidemiologisches Mosaik im Halbdunkeln. Neue Zürcher Zeitung, Wissenschaftl. Beilage, 123:87-88, 31.5.1989 Die Bedeutung des Quotienten von Spitzenkonzentration zu MHK für die Wirkung von Antibiotika. In: Parameter für die Beurteilung der Erregerempfindlichkeit - Fortschritte der antimikrobiellen und antineoplastischen Chemotherapie, 9-2, B. Wiedemann (Hrsg.), Futuramed-Verlag, München. pp. 191-201, 1990 Plädoyer für anonymisierte Reihenuntersuchungen zur Erhebung der Prävalenz und Inzidenz von HIV. Schweizerische Ärztezeitung 71:180-182, 1990 74. Blaser J, Einödter F, Battegay M, Ledergerber B, Lüthy R. Computergestütztes Monitoring von Antibiotika-Therapien. Nieren- und Hochdruckkrankheiten, 19:482-483, 1990 75. Simmen HP, Blaser J, Hänseler E. Verlaufskontrolle in der Abdominalchirurgie durch Analyse von pH, pO2 und pCO2 in der Drainageflüssigkeit. Helv Chir Acta 58, 717-720, 1991 Interactions of antimicrobial combinations in vitro: the relativity of synergism. Scand J Infect Dis, Suppl.74:71-79, 1991 Informationssysteme für die Klinik. Schweizerische Aerztezeitung, 72: 1895 - 1900, 1991 78. Keller H, Maurer P, Blaser J, Follath F. Miscellaneous antibiotics. In: Meyler's side effects of drugs, (Ed.: Dukes MNG), 12th edition. Elsevier Verlag, Amsterdam, New York & Oxford, 637-671, 1992 Einmaldosierung von Gentamicin? Dtsch Med Wschr 117: 1499-1500, 1992 Introduction to statistics on Macintosh. In: Advances in Statistical Software 3, SoftStat '91 (Ed. F. Faulbaum), Gustav Fischer Verlag, Stuttgart, pp. 361-366, 1992 Alternativen zum Tierversuch. Möglichkeiten und Grenzen am Beispiel der Antibiotikaforschung. Neue Zürcher Zeitung, Wissenschaftl. Beilage, 29:63, 5.2.1992 Informatikprojekte am Departement für Innere Medizin, Universitätsspital Zürich. VSAO-Bulletin, 11 (4): 71-74, 1992 Modell und Prototyp eines integrierten klinischen Informationssystems. Schweizerische Aerztezeitung, 74: 96 - 102, 1993 Antibiotic killing of suspended versus surface-associated Staphylococcus epidermidis. In: Molecular Pathogenesis of Surgical Infections, Academic Links Kalmar, pp. 226-239, 1994 Once-Daily Dosing of Aminoglycosides. Europ J Clin Microb Infect Dis 14: 1029-1038, 1995 In-vitro- und In-vivo-Untersuchungen von Antibiotika: Ursachen für Diskrepanzen. Chemotherapie Journal 4 (Suppl. 5): 18-24, 1995 87. Ruef C, Blaser J, Maurer P, Keller H, Follath F. Miscellaneous antibiotics. In: Meyler's side effects of drugs, (Ed.: Dukes MNG), 13th edition. Elsevier Verlag, Amsterdam, New York & Oxford, 725-773, 1996 Aminoglykoside einmal täglich dosieren. Schweiz Med Wochenschr 126, Suppl. 76: 39-48, 1996 Herausforderungen beim Aufbau und Betrieb von Klinikinformationssystemen. In: Klinikinformationssysteme von der Theorie zur Praxis (Ed. H.G. Koch), Schweiz. Gesellschaft Med. Informatik, Kongressband S. 75-77, 2. 1997 90. Ruffieux K, Wintermantel E, König C, Blaser J. Autosterilisation degradierbarer Implantate durch das Spritzgussverfahren. In: Hefte zu „Der Unfallchirurg“, Heft 265, L. Claes, A. Ignatius (Hrsg.), Bioresorbierbare Implantate und Materialien, Springer-Verlag, 1998 Benutzung von Literaturdatenbanken an einer Universitätsklinik. Schweizerische Aerztezeitung, 79:1410-1413, 1998 92. König C, Simmen HP, Blaser J. High bacterial concentrations in pus ans infected peritoneal fluid - Implications for bactericidal activity of antibiotics. J Antimicrob Chemother,43:425, 1999 Miscellaneous antibacterial drugs:aminoglycosides, chloramphenicol and thiamphenicol, fluoroquinolones, glycopeptides. In: Meyler's side effects of drugs, (Eds.: Dukes MNG and Aronson JK), 14th edition. Elsevier Verlag, Amsterdam, New York & Oxford, 837-870, 2000 94. Eschmann E, Mauron T, Blaser J. Schweiz Ärztezeitung 81(20):1049-55, 2000 95. T. Mauron, A. Schnyder, K. Krauer, M. Möckli, F. Salomon, Blaser J. Schrittweise Integration der Pflegedokumentation in das elektronische Patientendossier KISIM: Ein Erfahrungsbericht. Swiss Medical Informatics, 48:49-52, 2001 Zehn Jahre «KISIM» PULS 2:12-14, 2005 Der «Verlauf» – das Herzstück im KISIM PULS 4:6-7, 2005 98. Uesbeck M, Berger M, Blaser J. Die Integration der elektronischen Leistungserfassung nach TARMED in das Klinikinformationssystem KISIM. Swiss Medical Informatics, 54:14-17, 2005 Umfrage zu Kisim 2006: positiv und rascher Ausbau gefordert PULS, 4:11-12, 2006 Akzeptanz und Nutzen eines integrierten Klinikinformationssystems Swiss Medical Informatics, 61:4-6, 2007 Integration von Verordnungs- und Auftragsprozessen im Klinikinformationssystem des USZ. Swiss Medical Informatics, 62:47-52, 2007 Unterstützen Klinikinformationssysteme Forschung und Lehre? Swiss Medical Informatics, 65:40-42, 2008 Zugriffsberechtigungen in Klinikinformationssystemen. Swiss Medical Informatics, 68:34-36, 2010 Qualitätssteigerung bei der Thromboembolieprophylaxe dank eAlerts und Blockverordnungen. Swiss Medical Informatics, 69:33-36, 2010 Einführung und Akzeptanz des eKardex am UniversitätsSpital Zürich. Swiss Medical Informatics, 69:15-18, 2010


Patents ex parte decision (o/002/02)

COUNCIL REGULATION (EEC) NO. 1768/92 IN THE MATTER OF Application Nos. SPC/GB/96/030, SPC/GB/96/031, SPC/GB/96/032, SPC/GB/96/033, SPC/GB/96/034 and SPC/GB/96/035 in the name of Takeda Chemical Industries Limited DECISION The issues Takeda Chemical Industries Limited (“the applicant”) filed six requests for the grant of aSupplementary Protection Certificate (“certificate”) on

ADVANCED PAEDIATRIC CONSCIOUS SEDATION: AN ALTERNATIVE TO DENTAL GENERAL ANAESTHETIC IN THE UK. Hand DP1, Averley PA2, Lyne JP3, Girdler NM4. 1Senior House Officer, Department of Child Dental Health, Newcastle Dental Hospital. 2Principal General Dental Practitioner, Queensway Anxiety Management Clinic, Billingham, Teesside. 3Honorary Clinical Lecturer, Department of Sedation, Newcastle De

Copyright © 2010-2014 Medicament Inoculation Pdf